The effect of azacitidine on interleukin-6 signaling and nuclear factor-κB activation and its in vitro and in vivo activity against multiple myeloma

Haematologica

Volumn 93, Issue 6, 2008, Pages 860-869

  Khong, Tiffany ^a   Sharkey, Janelle ^a   Spencer, Andrew ^a  

^a ALFRED HOSPITAL   (Australia)

Author keywords

Bcl xl; Multiple myeloma; Nuclear factor B; SOCS3; Stat3

Indexed keywords

AZACITIDINE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR ALPHA; PROTEIN BCL XL; PROTEIN P16; STAT3 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DNA BINDING; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; GENE; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; METHYLATION; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; P16 GENE; PROTEIN ANALYSIS; PROTEIN SYNTHESIS INHIBITION; SURVIVAL TIME;

ACTIVE TRANSPORT, CELL NUCLEUS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; AZACITIDINE; BCL-X PROTEIN; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; MULTIPLE MYELOMA; NF-KAPPA B; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TETRAZOLIUM SALTS;

EID: 44949128833     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.12261     Document Type: Article

References (59)

1. Kyle RA. Diagnosis of multiple myeloma. Semin Oncol 2002;29:2-4.
2. Smith A, Wisloff F, Samson D, Forum UKM, Nordic Myeloma Study G, British Committee for Standards in Haematology. Guidelines on the diagnosis and management of multiple myeloma. Br J Haematol 2005;132: 410-51.
3. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-7.
4. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-83.
5. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998;16:593-602.
6. McCloskey EV, Dunn JA, Kanis JA, MacLennan IC, Drayson MT. Longterm follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol 2001;113: 1035-43.
7. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71.
8. Anderson KC. Moving disease biology from the lab to the clinic. Cancer 2003;97:796-801.
9. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. N Engl J Med 2005; 352:2487-98.
10. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004;64:1546-58.
11. Chesi M, Nardini E, Brents LA, Schröck E, Ried T, Kuehl WM, et al. Frequent translocation t(4;14)(p16.3; q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997;16:260-4.
12. Moreau P, Facon T, Leleu X, Morineau N, Huyghe P, Harousseau JL, et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002;100: 1579-83.
13. Perez-Simon JA, Garcia-Sanz R, Tabernero MD, Almeida J, González M, Fernández-Calvo J, et al. Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes. Blood 1998;91:3366-71.
14. Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH, et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995;86:4250-6.
15. Drexler HG. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia 1998;12:845-59.
16. Guillerm G, Gyan E, Wolowiec D, Facon T, Avet-Loiseau H, Kuliczkowski K, et al. p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. Blood 2001;98:244-6.
17. Mateos MV, Garcia-Sanz R, Lopez-Perez R, Moro MJ, Ocio E, Hernández J, et al. Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. Br J Haematol 2002;118:1034-40.
18. Takahashi T, Shivapurkar N, Reddy J, Shigematsu H, Miyajima K, Suzuki M, et al. DNA methylation profiles of lymphoid and hematopoietic malignancies. Clin Cancer Res 2004;10:2928-35.
19. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-7.
20. Mateos MV, Garcia-Sanz R, Lopez-Perez R, Balanzategui A, González MI, Fernández-Calvo J, et al. p16/INK4a gene inactivation by hypermethylation is associated with aggressive variants of monoclonal gammopathies. Hematol J 2001;2:146-9.
21. Glover AB, Leyland-Jones BR, Chun HG, Davies B, Hoth DF. Azacitidine: 10 years later. Cancer Treat Rep 1987;71:737-46.
22. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980;20:85-93.
23. Jones PA, Taylor SM, Wilson V. DNA modification, differentiation, and transformation. J Exp Zool 1983; 228: 287-95.
24. Kiziltepe T, Hideshima T, Catley L, Raje N, Yasui H, Shiraishi N, et al. 5-azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-stranded break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma. Mol Cancer Ther 2007; 6:1718-27.
25. Kornblith AB, Herndon JE 2nd, Silverman LR, Demakos EP, Odchimar-Reissig R, Holland JF, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 2002;20: 2441-52.
26. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002;20:2429-40.
27. Ullman-Cullere MH, Foltz CJ. Body condition scoring: a rapid and accurate method for assessing health status in mice. Lab Anim Sci 1999; 49:319-23.
28. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myeloma. Nature 1988;322:83-5.
29. Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood 1995;85:863-72.
30. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999;10:105-15.
31. Bonizzi G, Kaein M. The two NF-kB pathways and their role in innate and adaptive immunity. Trends Immunol 2004;25:280-8.
32. Karin M. Nuclear factor-kB in cancer development and progression. Nature 2006;441:431-6.
33. Kim HJ, Hawke N, Baldwin AS. NFkB and IKK as therapeutic targets in cancer. Cell Death Differ 2006;13:738-47.
34. Dalton WS, Jove R. Drug resistance in multiple myeloma: approaches to circumvention. Semin Oncol 1999;26: 23-7.
35. Yang HH, Ma MH, Vescio RA, Berenson JR. Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis. J Clin Oncol 2003; 21:4239-47.
36. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005;106:4050-3.
37. Marcucci G, Silverman L, Eller M, Lintz L, Beach CL. Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J Clin Pharmacol 2005;45:597-602.
38. Manning LS, Berger JD, O'Donoghue HL, Sheridan GN, Claringbold PG, Turner JH. A model of multiple myeloma: culture of 5T33 murine myeloma cells and evaluation of tumorigenicity in the C57BL/KaLwRij mouse. Br J Cancer 1992;66:1088-93.
39. Glover AB, Leyland-Jones BR. Biochemistry of azacitidine: a review. Cancer Treat Rep 1987;71:959-64.
40. Zwelling LA, Minford J, Nichols M, Glazier RI, Shackney S. Enhancement of intercalator-induced deoxyribonucleic acid scission and cytotoxicity in murine leukemia cells treated with 5-azacytidine. Biochem Pharmacol 1984;33:3903-6.
41. Karpf AR, Moore BC, Ririe TO, Jones DA. Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2′-deoxycytidine. Mol Pharmacol 2001;59:751-7.
42. Schwarze MM, Hawley RG. Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin6-mediated upregulation of bcl-x. Cancer Res 1995;55:2262-5.
43. Frassanito MA, Cusamai A, Iodice G, Dammacco F. Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. Blood 2001;97:483-9.
44. Klein B, Zhang XG, Jourdan M, Content J, Houssiau F, Aarden L, et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989;73:517-26.
45. Westendorf JJ, Ahmann GJ, Armitage MK, Spriggs MK, Lust JA, Greipp PR, et al. CD40 expression in malignant plasma cells: role in stimulation of autocrine Il-6 secretion by a human myeloma cell line. J Immunol 1994; 152:117-28.
46. Peters M, Jacobs S, Ehlers M, Vollmer P, Müllberg J, Wolf E, et al. The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble Il-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med 1996; 183:1399-406.
47. Akira S, Nishio Y, Inoue M, Wang XJ, Wei S, Matsusaka T, et al. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 1994;77:63-71.
48. Wegenka UM, Buschmann J, Lutticken C, Heinrich PC, Horn F. Acute-phase response factor, a nuclear factor binding to acutephase response elements, is rapidly activated by interleukin-6 at the posttranslational level. Mol Cell Biol 1993;13: 276-88.
49. Zhong Z, Wen Z, Darnell JE Jr. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994;264:95-8.
50. Tu Y, Renner S, Xu F, Taylor J, Weisz J, Vescio R, et al. BCL-X expression in multiple myeloma: possible indicator of chemoresistance. Cancer Res 1998; 5:256-62.
51. Bataille R, Barlogie B, Lu ZY, Rossi JF, Lavabre-Bertrand T, Beck T, et al. Biologic effects of anti-interleukin-6 monoclonal antibody in advanced multiple myeloma. Blood 1995;86:685-91.
52. De Vos J, Jourdan M, Tarte K, Jasmin C, Klein B. JAK2 tyrosine kinase inhibitor tyrphostin downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells. Br J Haematol 2000; 109:823-8.
53. Alas S, Bonavida B. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res 2003;9:316-26.
54. Nakanishi C, Toi M. Nuclear factorkB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005; 5:297-309.
55. Sharkey J, Khong T, Spencer A. PKC412 demonstrates JNK-dependent activity against human multiple myeloma cells. Blood 2006; 109:1712-9.
56. Fahy BN, Schlieman MG, Virudachalam S, Bold RJ. Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer. J Surg Res 2003;113:88-95.
57. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101:2377-80.
58. Tergaonkar V, Bottero V, Ikawa M, Li Q, Verma IM. IkB kinase-indepedent IkBa degradation pathway: functional NF-kB activity and implications for cancer therapy. Mol Cell Biol 2003; 23:8070-83.
59. Tatetsu H, Okuno Y, Nakamura M, Matsuno F, Sonoki T, Taniguchi I, et al.Dehydroxymethylepoxyquinomi cinb a novel nuclear factor-kB inhibitor, induces apoptosis in multiple myeloma cells in an IkBa-independent manner. Mol Cancer Ther 2005;4:1114-20.